Lurasidone: An antipsychotic with antidepressant effects in bipolar depression?

Australasian Psychiatry

Volumn 24, Issue 3, 2016, Pages 289-291

  Keks, Nicholas A ^a,b   Hope, Judy ^a,b   Castle, David ^c  

^a MONASH UNIVERSITY   (Australia)

^b Delmont Private Hospital   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bipolar depression; Lurasidone; Pharmacotherapy; Schizophrenia

Indexed keywords

FLUOXETINE; LITHIUM; LURASIDONE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; VALPROIC ACID; ZIPRASIDONE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

AGITATION; AKATHISIA; ANTIDEPRESSANT ACTIVITY; ARTICLE; BIPOLAR DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PARKINSONISM; PHARMACODYNAMICS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; STEADY STATE; WEIGHT GAIN; BIPOLAR DISORDER; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; LURASIDONE HYDROCHLORIDE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84978633551     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1177/1039856216641309     Document Type: Article

References (16)

1. Harvey PD. Lurasidone. In: Schatzberg A and Nemeroff C (eds) Essentials of clinical psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Publishing, 2013, pp. 361-366.
2. Servier Laboratories. Product information. Latuda (lurasidone hydrochloride). Hawthorn, Australia: Servier Laboratories Pty Ltd, 7 September 2015.
3. Therapeutic Goods Administration. Australian public assessment report for lurasidone hydrochloride. Woden, ACT: Commonwealth of Australia, 2014.
4. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-And olanzapine-controlled study. Am J Psychiatry 2011; 168: 957-967.
5. Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12 month, double-blind, noninferiority study. Schiz Res 2013; 147: 95-102.
6. Citrome L, Cuchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12 month, double-blind, active controlled study. Int Clin Psychopharm 2012; 27: 165-178.
7. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-Analysis. Lancet 2013; 382(9896): 951-962.
8. Harvey PD, Ogasa M, Cucchiaro J, et al. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs ziprasidone. Schiz Res 2011; 127: 188-194.
9. Harvey PD, Siu CO, Hsu J, et al. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo-And active-controlled study followed by a 6-month double-blind extension. Europ Neuropsychopharm 2013; 23: 1373-1382.
10. Harvey PD. The clinical utility of lurasidone in schizophrenia: patient considerations. Neuropsychiatr Dis Treat 2015; 11: 1103-1109.
11. Loebel A, Cuchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomised, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171: 160-168.
12. Loebel A, Cuchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate to the treatment of bipolar I depression: a randomised, double-blind, placebocontrolled study. Am J Psychiatry 2014; 171: 169-177.
13. Stahl SM. Stahl's essential psychopharmacology. Prescribers guide. 5th ed. New York: Cambridge University Press, 2014.
14. Calabrese JR, Hirschfield R, Frye MA, et al. Impact of depressive symptoms compared with manic symptoms and bipolar disorder: results of a US community-based sample. J C Psychiatry 2004; 65: 1199-1104.
15. Taylor DM, Cornelius V, Smith L, et al. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-Analysis. Acta Psychiatri Scand 2014; 130: 452-469.
16. Franklin R, Zorowitz, Corse A, et al. Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatr Dis and Treat 2015; 11: 2143-2152.